Your browser doesn't support javascript.
loading
Evaluation and validation of a PrintrLab-based LAMP assay to identify Trypanosoma cruzi in newborns in Bolivia: a proof-of-concept study.
Rojas Panozo, Lizeth; Rivera Nina, Silvia; Wehrendt, Diana P; Casellas, Aina; Pinto, Lilian; Mendez, Susana; Kuo, Chi-Wei; Lozano, Daniel F; Ortiz, Lourdes; Pinazo, Maria-Jesus; Picado, Albert; Sanz, Sergi; Abril, Marcelo; Gascon, Joaquim; Wong, Season; Schijman, Alejandro G; Torrico, Faustino; Alonso-Padilla, Julio.
Afiliação
  • Rojas Panozo L; Fundación Ciencias y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia.
  • Rivera Nina S; Fundación Ciencias y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia.
  • Wehrendt DP; Laboratorio de Biología Molecular de La Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI), Buenos Aires, Argentina.
  • Casellas A; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain.
  • Pinto L; Fundación Ciencias y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia.
  • Mendez S; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain.
  • Kuo CW; AI Biosciences, College Station, TX, USA.
  • Lozano DF; Fundación Ciencias y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia; Universidad Mayor de San Simón, Cochabamba, Bolivia.
  • Ortiz L; Plataforma de Chagas Tarija - Universidad Autónoma Juan Misael Saracho, Tarija, Bolivia.
  • Pinazo MJ; Drugs for Neglected Diseases Initiative (DNDi), Rio de Janeiro, Brazil; CIBER de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Picado A; Foundation for Innovative Diagnostics (FIND), Geneva, Switzerland.
  • Sanz S; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain.
  • Abril M; Fundación Mundo Sano, Buenos Aires, Argentina.
  • Gascon J; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • Wong S; AI Biosciences, College Station, TX, USA.
  • Schijman AG; Laboratorio de Biología Molecular de La Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI), Buenos Aires, Argentina.
  • Torrico F; Fundación Ciencias y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES), Cochabamba, Bolivia; Universidad Mayor de San Simón, Cochabamba, Bolivia.
  • Alonso-Padilla J; Barcelona Institute for Global Health (ISGlobal), Hospital Clinic - University of Barcelona, Barcelona, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain. Electronic address: julio.a.padilla@isglobal.org.
Lancet Microbe ; 2024 Jun 21.
Article em En | MEDLINE | ID: mdl-38971173
ABSTRACT

BACKGROUND:

Vertical transmission of Trypanosoma cruzi represents approximately 20% of new Chagas disease cases. Early detection and treatment for women of childbearing age and newborns is a public health priority, but the lack of a simple and reliable diagnostic test remains a major barrier. We aimed to evaluate the performance of a point-of-care loop-mediated isothermal amplification (LAMP) assay for the detection of T cruzi.

METHODS:

In this proof-of-concept study, we coupled a low-cost 3D printer repurposed for sample preparation and amplification (PrintrLab) to the Eiken T cruzi-LAMP prototype to detect vertically transmitted T cruzi, which we compared with standardised PCR and with the gold-standard algorithm (microscopy at birth and 2 months and serological study several months later). We screened pregnant women from two hospitals in the Bolivian Gran Chaco province, and those who were seropositive for T cruzi were offered the opportunity for their newborns to be enrolled in the study. Newborns were tested by microscopy, LAMP, and PCR at birth and 2 months, and by serology at 8 months.

FINDINGS:

Between April 23 and Nov 17, 2018, 986 mothers were screened, among whom 276 were seropositive for T cruzi (28·0% prevalence, 95% CI 25·6-31·2). In total, 224 infants born to 221 seropositive mothers completed 8 months of follow-up. Congenital transmission was detected in nine of the 224 newborns (4·0% prevalence, 1·9-7·5) by direct microscopy observation, and 14 more cases were diagnosed serologically (6·3%, 3·6-10·3), accounting for an overall vertical transmission rate of 10·3% (6·6-15·0; 23 of 224). All microscopy-positive newborns were positive by PrintrLab-LAMP and by PCR, while these techniques respectively detected four and five extra positive cases among the remaining 215 microscopy-negative newborns.

INTERPRETATION:

The PrintrLab-LAMP yielded a higher sensitivity than microscopy-based analysis. Considering the simpler use and expected lower cost of LAMP compared with PCR, our findings encourage its evaluation in a larger study over a wider geographical area.

FUNDING:

Inter-American Development Bank.

Texto completo: 1 Base de dados: MEDLINE País/Região como assunto: America do sul / Bolivia Idioma: En Revista: Lancet Microbe Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bolívia

Texto completo: 1 Base de dados: MEDLINE País/Região como assunto: America do sul / Bolivia Idioma: En Revista: Lancet Microbe Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bolívia